What is the clinical evidence from this study?

Population: Experimental arrhythmias. Intervention: AH-1058 vs. Disopyramide and verapamil. Primary outcome: Incidence of premature ventricular complex, ventricular tachycardia, and ventricular fibrillation.

What does this research mean for the field?

AH-1058 is a novel antiarrhythmic agent that inhibits ouabain- and reperfusion-induced ventricular arrhythmias and suppresses L-type Ca2+ currents, exhibiting a pharmacological profile distinct from disopyramide and verapamil. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

April 1, 1999Journal of Cardiovascular Pharmacology

Effects of AH-1058, a New Antiarrhythmic Drug, on Experimental Arrhythmias and Cardiac Membrane Currents

View Full Paper

Ask AI

Bookmark

Key result

AH-1058 inhibited ouabain- and reperfusion-induced ventricular arrhythmias and suppressed L-type Ca2+ currents in experimental animal models.

Why the study?

Does AH-1058 prevent experimental arrhythmias in animal models?

Structured PICO

Does AH-1058 prevent experimental arrhythmias in animal models?

Population

Guinea pig ouabain-induced arrhythmia model, rat reperfusion-induced arrhythmia model (5-min coronary occlusion and 10-min reperfusion), rat aconitine-induced arrhythmia model, and isolated guinea pig cardiomyocytes

Intervention

AH-1058 (0.1-0.3 mg/kg i.v., 1 mg/kg i.v., or 2-4 mg/kg oral)

Comparator

Disopyramide (5-10 mg/kg i.v.) and verapamil (1 mg/kg i.v.)

Outcome

Appearance of premature ventricular complex (PVC) and ventricular fibrillation (VF), incidence of ventricular tachycardia (VT) and VF, and L-type Ca2+ currentssurrogate

AH-1058 is a novel antiarrhythmic agent with Ca2+ channel-blocking properties that effectively suppresses ouabain- and reperfusion-induced arrhythmias in experimental models.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Hypothesis-generating for AH-1058 in ventricular arrhythmias; human trials needed before clinical consideration.

Cite This Study

Takahara et al. (1999) studied Experimental arrhythmias. AH-1058 vs. Disopyramide and verapamil was evaluated on Incidence of premature ventricular complex, ventricular tachycardia, and ventricular fibrillation. AH-1058 inhibited ouabain- and reperfusion-induced ventricular arrhythmias and suppressed L-type Ca2+ currents in experimental animal models.

synapsesocial.com/papers/6a1c824f0e2acd31eb2fd3e5 https://doi.org/10.1097/00005344-199904000-00016

View Full Paper

Ask AI

Bookmark

Effects of AH-1058, a New Antiarrhythmic Drug, on Experimental Arrhythmias and Cardiac Membrane Currents

Structured PICO

Discussion

Implication

Cite This Study

Effects of AH-1058, a New Antiarrhythmic Drug, on Experimental Arrhythmias and Cardiac Membrane Currents

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider